Ascletis Approved to Start US Trials of an Oral PD-L1 for Solid Tumors
publication date: Feb 8, 2022
Ascletis, a Hangzhou pharma, announced the US FDA has approved the company's IND for its self-developed oral PD-L1 small molecule inhibitor. ASC61 will be tested as a therapy for advanced solid tumors. Ascletis said that ASC61, an oral drug, will be easier to administer than injectable PD-1/PD-L1 antibodies. The approval was Ascletis' second US IND approval in 2022 following envafolimab, a possible cure for chronic hepatitis B. Ascletis started with a focus on anti-viral drugs with an emphasis on hepatitis C and has expanded into oncology. More details....
Stock Symbol: (HK: 1672)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.